Glutamatergic Amino Acids and Oxytocin Levels in the Plasma of Patients in First Psychotic Episode (FPE)- Before and After Neuroleptic Treatment
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00789022|
Recruitment Status : Unknown
Verified November 2008 by Shalvata Mental Health Center.
Recruitment status was: Not yet recruiting
First Posted : November 11, 2008
Last Update Posted : November 11, 2008
The goal of our research is to check the levels of D-Serine, Glycine, and other Glutamatergic amino acids, in patients with First Psychotic Episode (FPE). These patients are in the early stage of the disease, treated with neuroleptics for short periods of time, and are usually hospitalized for the first time. The hypothesis of the research is that we will find low levels of Glycine and D-Serine in these patients. Following an Anti-psychotic treatment we will expect these levels to return to the norm, and that this correction will be accompanied by a reduction of positive and negative symptoms.
In addition, we will check the D-Serine and Glycine levels in the plasma of first degree relatives of the patients and a group of healthy subjects. The results of this study might support the hypothesis that the Glutamatergic system in involved in the pathology of Schizophrenia from it's early stages.
In addition, we will check the levels of Oxytocin and Estrogen in the plasma of patients in FPE. Our hypothesis is that we will find low levels of Estrogen and High levels of Oxytocin in this group of patients. The results of the study might support the hypothesis that Estrogen and Oxytocin are involved in the pathology of Schizophrenia from it's early stages.
|Condition or disease|
|Schizophrenia Schizophreniform Schizoaffective Disorder Brief Psychotic Episode|
|Study Type :||Observational|
|Estimated Enrollment :||80 participants|
|Study Start Date :||January 2009|
|Estimated Primary Completion Date :||July 2010|
40 subjects in a First Psychotic Episode
20 First Degree relatives
20 Healthy subjects
- Glycine and D-Serine levels in the plasma. [ Time Frame: 6-8 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00789022
|Contact: Uri Nitzan, Mdemail@example.com|
|Contact: Uriel Levi-Herscho, MD||00-972-2-5316906||uriel heresco-levy [firstname.lastname@example.org]|
|Shalvata Medical Center||Active, not recruiting|
|Hod Hasharom, Israel|